UCELLO THERAPEUTICS
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
UCELLO THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2020-12-01
Address:
Chengdu, Sichuan, China
Country:
China
Website Url:
http://www.ucello.cn
Status:
Active
Contact:
+86 028 84729134
Email Addresses:
[email protected]
Total Funding:
25 M USD
Technology used in webpage:
SPF Alibaba
Similar Organizations
Alchemab Therapeutics
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Investors List
Northern Light Venture Capital
Northern Light Venture Capital investment in Series A - Ucello Therapeutics
Elikon Venture
Elikon Venture investment in Series A - Ucello Therapeutics
Chengdu Tianfu International Bio-Town Investment & Development
Chengdu Tianfu International Bio-Town Investment & Development investment in Series A - Ucello Therapeutics
Cowin Venture
Cowin Venture investment in Series A - Ucello Therapeutics
Matrix Partners China
Matrix Partners China investment in Series A - Ucello Therapeutics
